DAA-PASS: A Post-Authorisation Safety Study of Early Recurrence of Hepatocellular Carcinoma in HCV-Infected Patients after Direct-Acting Antiviral Therapy

01/03/2018
23/04/2024
EU PAS number:
EUPAS22896
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

TARGET-HCC_DAA-PASS_Protocol_v3_3_06Jun2018_Final

English (967.39 KB - PDF) View document
Updated protocol

TARGET-HCC_DAA-PASS_Protocol_v6.0

First published: 22/02/2024
English (1.26 MB - PDF) View document
Study results
Study results

DAA-PASS CSR Abstract 2.0_Final_Redacted

English (468.72 KB - PDF) View document

DAA-PASS CSR Abstract Final v5.0_ 16 Dec 2021

English (92.22 KB - PDF) View document
Study report
Other information